Mark Eisner - Jul 15, 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
EVP and Chief Medical Officer
Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Stock symbol
VIR
Transactions as of
Jul 15, 2024
Transactions value $
$0
Form type
4
Date filed
7/16/2024, 04:40 PM
Previous filing
Jun 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +75K $0.00 75K Jul 15, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +150K $0.00 150K Jul 15, 2024 Common Stock 150K $9.37 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2 25% of the shares subject to the stock option vest and become exercisable on July 15, 2025, and the remainder vest in 36 equal monthly installments thereafter.